The biotech industry is undergoing a seismic transformation, powered by artificial intelligence (AI). From drug discovery to diagnostics, AI-powered tools are accelerating research timelines, lowering costs, and pushing the boundaries of precision medicine. But even as biotech becomes more digitized, one need remains unchanged: access to flexible, collaborative, and high-quality lab space.

‍

World-class shared labs are an ideal fit for this new wave of biotech-AI hybrids—companies that blend computational power with experimental rigor. Labshares is uniquely positioned to serve them, offering a capital-efficient, fully equipped environment that matches the pace and flexibility these ventures demand.

‍

AI’s Growing Footprint in Biotech

‍

In 2024 alone, over 40% of newly funded biotech startups in the U.S. reported integrating AI into their core operations, particularly in drug discovery and -omics analysis. With more than $4.2 billion invested in AI-biotech platforms, venture capital is gravitating toward technologies that combine machine learning with experimental validation.

‍

This surge is transforming biotech workflows: drug candidates are being identified up to 70% faster, biomarker discovery is improving, and lab operations are becoming more efficient thanks to machine learning–driven robotics.

‍

The bottomline: AI is speeding up the scientific process and generating insights at an unprecedented scale

‍

Why AI Biotechs Still Need Physical Lab Space

‍

Despite their digital capabilities, AI-driven biotech companies still rely heavily on wet lab experimentation. Here’s why shared lab space remains essential:

‍

• Model Validation: AI-predicted drug candidates or biomarkers must still be tested in vitro and in vivo, requiring well-equipped lab benches and access to specialized equipment.

‍

• Hybrid Teams: These companies are often built by multidisciplinary teams—data scientists, molecular biologists, and chemists—who need a place to come together  and collaborate in real time.

‍

• Rapid Iteration: The synergy between computational predictions and experimental feedback loops demands close, agile workflows that are best served by local lab access.

‍

• Cost Control: Early-stage companies can’t afford to build their own infrastructure. Flexible, plug-and-play lab spaces like Labshares help them scale without overcommitting capital.

‍

How Labshares Bridges the Gap

‍

At Labshares, we provide more than just space—we offer an ecosystem designed for innovation:

‍

• State-of-the-Art Lab Facilities: Fully customizable benches and suites, $7M of shared equipment, and all backend lab services.

‍

• Flexible Membership Models: Flexible licensing terms designed to grow with your needs.

‍

• Tech-Forward Amenities: Reliable data connectivity, secure access, and support for computational workflows.

‍

• VibrantCommunity: A built-in network of founders, scientists, and investors at the cutting edge of biotech and AI.

‍

Labshares is already home to several AI-driven biotech ventures. While many of these companies are powered by data and computation, they still rely on wet lab space for validation and development—something Labshares is uniquely equipped to provide. We offer the infrastructure, flexibility, and collaborative environment that allow AI-biotech innovators to bring their digital insights into physical form.

‍

AI is not replacing the lab—it’s redefining its role. And Labshares is here to support the scientists and companies leading this change.

‍

‍

‍

‍

‍

‍